STOCK TITAN

Cryo-Cell Intl Inc - CCEL STOCK NEWS

Welcome to our dedicated page for Cryo-Cell Intl news (Ticker: CCEL), a resource for investors and traders seeking the latest updates and insights on Cryo-Cell Intl stock.

Overview

Cryo-Cell International Inc (CCEL) has established itself as a foundational entity in the realm of cellular processing, cryogenic storage, and stem cell banking. As the oldest cord blood bank in the industry, the company offers comprehensive services that include the collection, processing, and cryopreservation of umbilical cord blood, cord tissue, and menstrual stem cells. By controlling every facet of the processing and storage cycle, Cryo-Cell ensures that the integrity and viability of stem cell specimens are maintained, which is a critical differentiator in a highly specialized field. This detailed approach supports both family-directed private banking and public banking initiatives, allowing for versatile use across different market segments.

Historical Background

Founded in 1989, Cryo-Cell International Inc pioneered the establishment of a cord blood banking framework. The company became the first to separate and process stem cells from umbilical cord blood in 1992, setting industry benchmarks for quality and procedural rigor. With decades of operational history, Cryo-Cell has built an international clientele and a reputation for excellence underpinned by stringent internal controls and robust quality assurance protocols.

Business Segments and Core Operations

The company’s operations are organized into distinct, reportable segments that underline its diversified business model:

  • Cellular Processing and Cryogenic Storage: This segment focuses on the collection and preservation of umbilical cord blood and tissue stem cells for families. Cryo-Cell uses advanced processing technologies to ensure the viability of specimens under rigorous storage conditions.
  • PrepaCyte CB Processing Technology: This specialized segment involves a proprietary method used to process umbilical cord blood stem cells, aimed at maximizing the concentration of stem cells in the final product. This advanced technology exemplifies the company’s commitment to innovation and enhanced biological processing techniques.
  • Public Cord Blood Banking: In addition to private banking, Cryo-Cell also offers public banking services. This segment involves the processing and cryogenic storage of cord blood stem cells for broader community use and research applications.

Revenue is primarily generated through processing and testing fees along with storage fees, reflecting a business model that combines both transactional service delivery and long-term asset management. This dual approach serves to stabilize financial inputs while ensuring that cutting-edge technology and quality standards are consistently applied throughout operations.

Technological Capabilities and Quality Assurance

Cryo-Cell operates with a state-of-the-art processing, testing, and cryopreservation facility that allows for complete operational control. The company’s infrastructure is pivotal in maintaining specimen viability and ensuring that every step adheres to the highest quality standards. A particularly noteworthy achievement is the company’s historic record of 100% specimen viability upon thaw, which underscores its meticulous laboratory practices and advanced cryogenic technology. These attributes not only bolster trust but also demonstrate deep expertise in the field.

Competitive Landscape and Market Position

Within the highly specialized market of stem cell banking, Cryo-Cell International Inc holds a distinctive position. The company’s comprehensive in-house processing capabilities, paired with its proactive approach to technology development, allow it to address both the private and public demands of the market. Unlike many competitors that rely on outsourced processing, Cryo-Cell’s vertical integration enables rapid response to quality issues and ensures that the highest standards are met from collection to storage.

Furthermore, the company’s focus on diverse business segments, including the manufacturing of specialized processing units (such as the PrepaCyte CB), illustrates its commitment to continuous improvement in cellular medical technologies. This strategic positioning has helped create a robust profile among stakeholders who value technological innovation and quality assurance in the life sciences industry.

Operational Excellence and Industry Expertise

The operational model at Cryo-Cell is built on a commitment to technical excellence and process optimization. Every specimen undergoes rigorous testing protocols before and after cryopreservation, ensuring that the final product meets stringent viability criteria. This holistic approach not only instills confidence in clients but also reinforces the company’s status as an expert in cellular therapeutics and regenerative medicine.

Quality, Reliability, and Trustworthiness

Quality assurance is a cornerstone of Cryo-Cell’s business philosophy. Every phase of the cord blood and tissue processing workflow is designed to prevent contamination and degradation, thereby anchoring the company’s reputation for reliability. By consistently delivering specimens that meet high standards of viability, Cryo-Cell engenders trust within a community that includes families, researchers, and medical professionals.

Industry Impact and Legacy

Cryo-Cell International Inc has contributed significantly to the evolution of cellular therapies and regenerative medicine. Its early adoption and development of cord blood banking processes have paved the way for subsequent innovations within the industry. Even as the field evolves, the company’s commitment to quality and its pioneering spirit continue to influence best practices within the domain of cellular processing and cryogenic storage.

In summary, Cryo-Cell International Inc serves as an instructive case study for best practices in the storage and processing of stem cells. With a longstanding foundation, diversified business segments, and a relentless focus on quality assurance, the company offers a robust example of expertise and operational excellence within the healthcare and biotechnology industries.

Rhea-AI Summary

Cryo-Cell International has announced plans for its Institute for Cellular Therapies after securing an exclusive license from Duke University. This partnership provides commercial rights to a range of FDA regulatory data and intellectual property related to cord blood and cord tissue-derived cell therapies that passed Phase 1/Phase 2 trials. The company aims to conduct further Phase 2 and Phase 3 trials focusing on conditions like hypoxic ischemic encephalopathy, cerebral palsy, and autism. Successful trials could lead to FDA licensure and commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

On October 15, 2021, Cryo-Cell International (CCEL) reported Q3 2021 results, showing revenue of $7.5 million, an 8% decline from $8.1 million in Q3 2020. Processing and storage fees contributed $7.3 million. Net income was $857,000 ($0.10 per share), up from $784,000 in the prior year. Expenses increased, primarily due to costs related to the Cryo-Cell Institute and patent expenses. Despite revenue decline, the company emphasized solid results amid its transition to a vertically integrated cellular therapy entity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.5%
Tags
-
Rhea-AI Summary

Cryo-Cell International, Inc. (Nasdaq:CCEL) has appointed Mark Portnoy and Daniel Mizrahi to its Board of Directors, following the resignations of George Gaines and Jonathan Wheeler, M.D. Gaines retires while Wheeler steps down for health reasons. Both new appointees bring extensive experience, with Portnoy having previously served on the board and Mizrahi leading a manufacturing company in Guatemala. The board expects to enhance shareholder value, particularly after the recent NASDAQ uplisting and a transformative agreement with Duke University.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.51%
Tags
management
Rhea-AI Summary

Cryo-Cell International, Inc. (CCEL) has announced its common stock is listed on the Nasdaq Capital Market as of August 31, 2021. This milestone marks an achievement in meeting Nasdaq's stringent requirements and aims to enhance liquidity and broaden the shareholder base. Chairman David Portnoy expressed optimism that this uplisting will reduce the valuation gap between market and intrinsic value. Cryo-Cell is transitioning into a biopharmaceutical company, providing experimental treatments at the upcoming Cryo-Cell Institute for Cellular Therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.82%
Tags
none
-
Rhea-AI Summary

Cryo-Cell International (CCEL) has acquired an 8,326 sq. ft. facility in Durham, NC, for its Institute for Cellular Therapies, strategically located near the Raleigh-Durham International Airport. The clinic aims to provide FDA-approved clinical trials for patients in need of cord blood therapies by early 2022. This facility will employ advanced technology and child-friendly layout while adhering to COVID safety guidelines. The treatments target various conditions, including autism spectrum disorders and cerebral palsy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Cryo-Cell International, the world’s first cord blood bank, announced that Chairman and Co-CEO, David Portnoy, will present at the Q3 Virtual Investor Summit on August 18, 2021, at 2:45 PM EDT. The 30-minute session will include a 20-minute corporate overview followed by a 10-minute Q&A. In February 2021, Cryo-Cell transformed into a vertically integrated cellular therapy company through a license agreement with Duke University, set to treat patients at its first infusion clinic opening in early 2022. The event can be accessed via registration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Cryo-Cell International, Inc. (CCEL) reported its fiscal Q2 2021 results with a revenue decrease of 8% to $7.21 million, down from $7.87 million in Q2 2020. The company generated $7.16 million in processing and storage fees. Net income rose to $1.17 million, or $0.15 per basic share, from $953,000, or $0.13 per basic share in the prior year. Cost reductions in sales and administrative expenses contributed to net income growth despite lower revenues. Cryo-Cell continues to expand its operations and maintain quality standards with FDA registration and AABB accreditation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
-
Rhea-AI Summary

Cryo-Cell International is conducting two pivotal clinical studies: MASC for COVID-19 related Acute Respiratory Distress Syndrome and MISTIC for children with Multisystem Inflammatory Syndrome associated with COVID-19. MASC has completed Phase 1 and is enrolling for Phase 2, while MISTIC is in Phase 1 enrollment. Both studies utilize human cord tissue derived mesenchymal stromal cells. The ongoing research underscores Cryo-Cell's commitment to advancing regenerative medicine and improving patient outcomes amid the ongoing pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
covid-19
-
Rhea-AI Summary

Cryo-Cell International, Inc. (OTC: CCEL) reported its fiscal first quarter results for 2021, citing revenues of $6.86 million, a decrease from $7.62 million in Q1 2020. The revenue comprised $6.74 million from processing and storage fees, $38,000 from product sales, and $84,000 from public banking. Net income was approximately $694,000, consistent with the prior year. The company is optimistic about future opportunities tied to its licensing agreement with Duke University, despite challenges posed by the COVID-19 pandemic affecting birth rates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
Rhea-AI Summary

Cryo-Cell International, Inc. (CCEL) has entered a collaborative licensing agreement with Duke University to utilize proprietary processes and regulatory data pertaining to cord blood and tissue. This agreement allows Cryo-Cell to explore potential treatments for conditions with limited FDA approved therapies, including cerebral palsy, autism, multiple sclerosis, and COVID-19. Cryo-Cell is focusing on expanding its core business units, including biopharmaceutical manufacturing, pending necessary FDA approvals. The partnership raises the possibility of uplisting the stock to NASDAQ.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
none

FAQ

What is the current stock price of Cryo-Cell Intl (CCEL)?

The current stock price of Cryo-Cell Intl (CCEL) is $6.45 as of April 4, 2025.

What is the market cap of Cryo-Cell Intl (CCEL)?

The market cap of Cryo-Cell Intl (CCEL) is approximately 51.2M.

What is the core business of Cryo-Cell International Inc?

Cryo-Cell International Inc is primarily engaged in cellular processing and cryogenic storage with a focus on the collection, processing, and preservation of umbilical cord blood, cord tissue, and menstrual stem cells for both private and public banking.

How does Cryo-Cell ensure the quality and viability of stored specimens?

The company operates a state-of-the-art processing, testing, and cryopreservation facility with rigorous protocols that have resulted in a historical record of 100% viability upon thaw, ensuring the highest reliability and quality of stored specimens.

What distinguishes Cryo-Cell in the stem cell banking industry?

Cryo-Cell differentiates itself through complete operational control, proprietary processing technology like PrepaCyte CB, and a legacy of pioneering cord blood banking, which collectively contribute to its trusted reputation in cellular processing.

What are the main business segments of Cryo-Cell International Inc?

The company operates through multiple segments, including family-focused cellular processing and cryogenic storage, the specialized PrepaCyte CB processing technology unit, and a public cord blood banking segment that supports community and research needs.

How is revenue generated by Cryo-Cell International Inc?

Revenue is derived from processing and testing fees as well as storage fees, resulting from the company's comprehensive approach to managing the entire lifecycle of cord blood and tissue stem cell specimens.

How does Cryo-Cell maintain its competitive edge in the market?

The company maintains a competitive advantage through vertical integration of its processing and storage facilities, proprietary technology development, and a robust quality assurance framework that ensures the integrity of every stored specimen.

Is Cryo-Cell involved in both private and public banking?

Yes, Cryo-Cell offers services for both private family banking and public cord blood banking, catering to a wide range of needs from individual family use to community and research purposes.

What technological innovations are associated with Cryo-Cell?

Cryo-Cell has developed and implemented innovations such as the PrepaCyte CB processing technology, which enhances the processing of cord blood stem cells, ensuring improved concentration and quality of the preserved specimens.
Cryo-Cell Intl Inc

Nasdaq:CCEL

CCEL Rankings

CCEL Stock Data

51.16M
4.43M
47.59%
12.76%
0.18%
Medical Care Facilities
Services-misc Health & Allied Services, Nec
Link
United States
OLDSMAR